Post-traumatic stress disorder (PTSD) is a psychiatric disorder triggered by experiencing or witnessing a frightening event. PTSD can disrupt your entire life, such as your work, relationships, health, and your interest in everyday activities. Ace Therapeutics is a preclinical contract research and development organization focusing on the field of psychiatric disorders. To support the development of treatments for PTSD, we offer a range of preclinical R&D services. Our comprehensive portfolio of services covers PTSD animal models, drug screening, efficacy and safety assessments, biomarker studies and more. With our extensive experience and expertise, we will collaborate with you to accelerate the discovery and development of new therapies.

Key Targets for Anti-PTSD Drug Development

• 5-hydroxytryptamine receptors: 5-HT receptor agonists can improve symptoms of anxiety, fear, and stress, with 5-hydroxytryptamine 2A (5-HT2A) receptor agonists being the most commonly used.
• Gamma-aminobutyric acid (GABA) receptors: GABA receptor agonists can reduce post-traumatic anxiety and stress.
• N-methyl-D-aspartate receptors: NMDA receptor antagonists reduce the excitability of related neurons and alleviate the memory and emotional responses that arise after trauma.
• Muscarinic receptors: Muscarinic receptor antagonists modulate the level of acetylcholine in the brain and improve cognition and attention, among other things.
• Intracerebroventricular peptide receptors: Intracerebroventricular peptide receptor agonists reduce anxiety and stress and improve sleep quality.
• Peripheral benzodiazepine receptors: Peripheral benzodiazepine receptor antagonists counteract symptoms caused by stressful abiotic and other factors.

How Can We Help?

Pathophysiologic Mechanism Research Services of Post-Traumatic Stress Disorder (PTSD)

Ace Therapeutics employs a multi-disciplinary approach to PTSD research, combining animal models and in vitro cell culture systems to mimic the trauma response with molecular biology, neuroscience, and behavioral tests to comprehensively investigate the underlying neurophysiological and psychopathological mechanisms associated with PTSD. By leveraging high-throughput screening, neuroimaging analysis, and bioinformatics tools, we are committed to identifying biomarkers of PTSD, evaluating potential therapeutic targets, and offering our clients a comprehensive scientific support system, spanning from mechanism exploration to clinical application. Our research activities are focused on the following areas:

• Genetics and PTSD
• Inflammation and PTSD
• Neurotransmitter genomics and PTSD
• Metabolic changes and PTSD
• Neuroendocrine disturbances and PTSD
• Mitochondria and PTSD
• Neurogenesis and PTSD

Fig. 1 Physical changes associated with PTSD. (Aliev, G.; et al., 2020)

Preclinical Screening and Evaluation Services for PTSD Therapeutic Drugs

Ace Therapeutics provides preclinical development services for anti-PTSD agents, including early drug screening, pharmacokinetic and pharmacodynamic assessments, toxicological evaluations, drug metabolism, and drug interaction studies.

• Early drug screening: We can select compounds with potential anti-PTSD effects through preliminary in vitro or in vivo evaluation.
• Pharmacokinetic and pharmacodynamic evaluation: We can evaluate the absorption, distribution, metabolism, and excretion of drugs, as well as their effects on targets through in vivo pharmacokinetic (PK) and pharmacodynamic (PD) studies.
• Toxicological evaluation: We can evaluate the toxicity and safety of drugs for humans or animals, including acute toxicity, chronic toxicity, mutagenicity, carcinogenicity, reproductive toxicity, immunotoxicity, etc.
• Drug metabolism and drug interaction studies: We can study the metabolic pathways and metabolites of drugs, as well as the interactions between different drugs, including drug-drug interactions and drug-food interactions, etc.

Diagnostic Method Development Services for PTSD

Single Photon Emission Computed Tomography (SPECT) brain scans may offer a more accurate diagnosis of PTSD than other MRI and CT scans. Ace Therapeutics provides clients with a comprehensive approach to developing more accurate PTSD diagnostics, combining animal models, neuroimaging techniques, biomarker analysis, and artificial intelligence algorithms.

Related Services

• Post-Traumatic Stress Disorder (PTSD) Animal Models
• Conditioned Fear Tests for Psychiatric Disorders
• Antipsychotics Screening Services
• Antipsychotic Discovery and Preclinical Services
• Pharmacokinetics Analysis Services for Antipsychotics

Ace Therapeutics can provide a full range of support to pharmaceutical companies and research institutions to help them approve PTSD d therapeutic drugs as soon as possible. Our services can help reduce your development time and costs, improve the quality and efficacy of your drug, and provide specialized knowledge and skills. If you are interested in our services, please contact us to learn how we can support you in your project.

Reference

1. Aliev, G.; et al. Neurophysiology and psychopathology underlying PTSD and recent insights into the PTSD therapies-a comprehensive review. Journal of clinical medicine. 9.9 (2020): 2951.